Man Group PLC Kura Oncology, Inc. Transaction History

Man Group PLC

$37.2 Billion
Q1 2025

A detailed history of Man Group PLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Man Group PLC holds 156,064 shares of KURA stock, worth $945,747. This represents 0.0% of its overall portfolio holdings.

Number of Shares

156,064

Previous 18,705 734.34%

Holding current value

$945,747

Previous $162,000 535.8%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$6.6 - $9.05 $906,569 - $1.24 Million	137,359 Added 734.34%	156,064 $1.03 Million
Q4 2024 Feb 14, 2025	BUY	$8.51 - $19.21 $159,179 - $359,323	18,705 New	18,705 $162,000
Q1 2021 May 17, 2021	SELL	$24.75 - $39.14 $424,660 - $671,564	-17,158 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$29.0 - $41.62 $215,122 - $308,737	-7,418 Reduced 30.18%	17,158 $560,000
Q3 2020 Nov 16, 2020	BUY	$16.3 - $30.64 $100,717 - $189,324	6,179 Added 33.59%	24,576 $753,000
Q2 2020 Aug 14, 2020	BUY	$7.95 - $18.81 $37,261 - $88,162	4,687 Added 34.19%	18,397 $300,000
Q1 2020 May 15, 2020	SELL	$6.45 - $14.04 $594,877 - $1.29 Million	-92,229 Reduced 87.06%	13,710 $136,000
Q4 2019 Feb 18, 2020	SELL	$12.97 - $15.94 $1.91 Million - $2.35 Million	-147,446 Reduced 58.19%	105,939 $1.46 Million
Q3 2019 Nov 14, 2019	SELL	$14.75 - $20.87 $627,494 - $887,851	-42,542 Reduced 14.38%	253,385 $3.84 Million
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $2.93 Million - $3.94 Million	198,870 Added 204.9%	295,927 $5.83 Million
Q1 2019 May 15, 2019	BUY	$13.73 - $16.87 $1.33 Million - $1.64 Million	97,057 New	97,057 $1.61 Million

Others Institutions Holding KURA

# of Institutions

190

Shares Held

79M

Call Options Held

76K

Put Options Held

85.8K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $405M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account